512
Participants
Start Date
July 31, 2009
Primary Completion Date
February 28, 2010
Study Completion Date
February 28, 2010
Lasmiditan
Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
Placebo
Placebo
Brussels
Leuven
Hasselt
Liège
Montegnée
Bruges
Berlin
Santiago de Compostela
Turku
Hamburg
Itzehoe
Pori
Bremen
Alcorcón
Pamplona
Toulouse
Oviedo
Bordeaux
Tampere
Jyväskylä
Seville
Erkelenz
Essen
Valencia
Gandia
Münster
Mikkeli
Wiesbaden
Göppingen
Paris
Rouen
Freiburg/Breisgau
München
München
Helsinki
Hyvinkää
Nice
Lille
Barcelona
Collaborators (1)
CoLucid Pharmaceuticals
INDUSTRY
Eli Lilly and Company
INDUSTRY